Wet age\|related macular degeneration (AMD) is one of the main causes of vision loss in elderly people, and its etiology is not clear. In terms of pathogenesis, it has been confirmed that vascular endothelial growth factor and wet AMD have a clear correlation. Therefore, there are many kinds of anti\|vascular endothelial growth factor drugs used in the disease. Intravitreal Ranibizumab can inhibit vascular endothelial growth factor and block the growth and leakage of new blood vessels to play a role.The Ranibizumab has been shown to be a definite therapeutic effect in the treatment of wet AMD. The progress of Ranibizumab in the treatment of wet AMD is reviewed in this article, including the treatment efficacy, the factors of affecting the efficacy, the combined therapy, and the adverse reaction and so on.(Int Rev Ophthalmol, 2016, 40: 400-404)